Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.

Details

Serval ID
serval:BIB_044C379CA9CC
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Journal
Journal for immunotherapy of cancer
Author(s)
Ressler J.M., Karasek M., Koch L., Silmbrod R., Mangana J., Latifyan S., Aedo-Lopez V., Kehrer H., Weihsengruber F., Koelblinger P., Posch C., Kofler J., Michielin O., Richtig E., Hafner C., Hoeller C.
ISSN
2051-1426 (Electronic)
ISSN-L
2051-1426
Publication state
Published
Issued date
02/2021
Peer-reviewed
Oui
Volume
9
Number
2
Pages
e001701
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and demonstrated an overall response rate (ORR) of 40.5% and a complete response (CR) rate of 16.6%.
The aim of this study was to assess the outcome of melanoma patients treated with T-VEC in a real-life clinical setting.
Based on data from 10 melanoma centers in Austria, Switzerland and southern Germany, we conducted a retrospective chart review, which included 88 patients (44 male, 44 female) with a median age of 72 years (range 36-95 years) treated with T-VEC during the period from May 2016 to January 2020.
88 patients fulfilled the inclusion criteria for analysis. The ORR was 63.7%. 38 patients (43.2%) showed a CR, 18 (20.5%) had a partial response, 8 (9.1%) had stable disease and 24 (27.3%) patients had a progressive disease. The median treatment period was 19 weeks (range: 1-65), an average of 11 doses (range: 1-36) were applied. 39 (45.3%) patients developed adverse events, mostly mild, grade I (64.1%).
This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.
Keywords
immunotherapy, melanoma, oncolytic virotherapy, oncolytic viruses
Pubmed
Web of science
Open Access
Yes
Create date
01/03/2021 12:49
Last modification date
12/10/2021 5:40
Usage data